QUICK Corp.

Equity Bottom-Up

OP increased by 45% in 1H. Online shifts of pharmaceutical companies and clinics are progressing faster than expected
<ul>
<li>
The negative impact of COVID-19 has become less than expected Consolidated results for 1H of FY3/21 were sales revenue of JPY75bn (+22% YoY) and OP of JPY23.9bn (+45% YoY). In 1Q, they increased by 15% and 26%, respectively, but in 2Q, they increased by 28% and 66%, respectively. Structural changes in pharmaceutical companies and clinical practice sites due to COVID-19 were…</li>
</ul>

Notes: This is translated from our Japanese report issued on 30 Jul 2020.
<div>
In 1Q, OP increased by 26% YoY. Demand for pharmaceutical marketing support surged due to COVID-19
<ul>
<li>
Offsetting declines in clinical trials and employment services The consolidated financial results for 1Q FY3/21 were sales revenue of JPY35.5bn (+15% YoY) and OP of JPY11.3bn (+26% YoY). The core MP business led the overall business with a 32% YoY increase in sales and a 70% YoY increase in profits. With the spread of…</li>
</ul>
</div>

Japan

M3, Inc. supplies medical information services for doctors through the Internet. The Company also supports marketing of pharmaceutical companies and medical equipment manufacturers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00